JP2022533971A - 皮下注射のためのケタミン製剤 - Google Patents

皮下注射のためのケタミン製剤 Download PDF

Info

Publication number
JP2022533971A
JP2022533971A JP2021568611A JP2021568611A JP2022533971A JP 2022533971 A JP2022533971 A JP 2022533971A JP 2021568611 A JP2021568611 A JP 2021568611A JP 2021568611 A JP2021568611 A JP 2021568611A JP 2022533971 A JP2022533971 A JP 2022533971A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ketamine
compound
pain
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533971A5 (cg-RX-API-DMAC10.html
Inventor
ベッカー，ジェフリー
ピーターソン，グレッグ
ヴァラッハ，ジェイソン
Original Assignee
ベクソン バイオメディカル，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベクソン バイオメディカル，インク． filed Critical ベクソン バイオメディカル，インク．
Publication of JP2022533971A publication Critical patent/JP2022533971A/ja
Publication of JP2022533971A5 publication Critical patent/JP2022533971A5/ja
Priority to JP2025062046A priority Critical patent/JP2025114555A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021568611A 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤 Pending JP2022533971A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025062046A JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848420P 2019-05-15 2019-05-15
US62/848,420 2019-05-15
PCT/US2020/032941 WO2020232274A1 (en) 2019-05-15 2020-05-14 Ketamine formulation for subcutaneous injection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025062046A Division JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Publications (2)

Publication Number Publication Date
JP2022533971A true JP2022533971A (ja) 2022-07-27
JP2022533971A5 JP2022533971A5 (cg-RX-API-DMAC10.html) 2023-05-23

Family

ID=73230954

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568611A Pending JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤
JP2025062046A Pending JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025062046A Pending JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Country Status (7)

Country Link
US (2) US10973780B2 (cg-RX-API-DMAC10.html)
EP (2) EP3968979B1 (cg-RX-API-DMAC10.html)
JP (2) JP2022533971A (cg-RX-API-DMAC10.html)
CN (2) CN121489917A (cg-RX-API-DMAC10.html)
CA (1) CA3140046A1 (cg-RX-API-DMAC10.html)
ES (1) ES3075367T3 (cg-RX-API-DMAC10.html)
WO (1) WO2020232274A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025114555A (ja) * 2019-05-15 2025-08-05 ベクソン バイオメディカル，インク． 皮下注射のためのケタミン製剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
CN115942935B (zh) 2020-08-18 2025-09-05 奥克伍德实验室有限责任公司 包括氯胺酮的微球制剂及其制备和使用方法
US12685714B2 (en) 2020-08-18 2026-07-21 Oakwood Laboratories, Llc Microsphere formulations comprising ketamine and methods for making and using the same
EP4247340A4 (en) * 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
US20240336556A1 (en) * 2021-10-12 2024-10-10 Perception Neuroscience, Inc. R-ketamine salts and methods of use thereof
EP4493155A1 (en) * 2022-03-14 2025-01-22 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine
EP4525916A4 (en) * 2022-05-18 2026-05-20 Bexson Biomedical Inc LOW STOICHIOMETRIC RATIO SALT FORMULATIONS FOR COMPLEXING AGENTS OF PHARMACEUTICAL COMPOUNDS
IN202221054235A (cg-RX-API-DMAC10.html) 2022-09-22 2023-11-03
WO2024171074A1 (en) * 2023-02-15 2024-08-22 Clearmind Medicine Inc. Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072671A (ja) * 1993-03-05 1995-01-06 Univ Virginia Commonwealth 鎮痛剤
JPH11511466A (ja) * 1995-08-30 1999-10-05 スチュアート エル ウェグ 苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与
JP2002510653A (ja) * 1998-04-03 2002-04-09 カイロン コーポレイション 緩衝剤としてコハク酸を含有する注射可能なｉｇｆ処方物
JP2010525081A (ja) * 2007-04-26 2010-07-22 オースペックス・ファーマシューティカルズ・インコーポレイテッド 重水素標識ケタミン
JP2015501302A (ja) * 2011-10-14 2015-01-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2017180589A1 (en) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
SE501482C2 (sv) 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
DE69425948T2 (de) 1993-12-06 2001-02-22 Takeda Chemical Industries, Ltd. Zusammensetzung mit verbesserter Wasserlöslichkeit, enthaltend eine Wasserunlösliche oder an Wasser schwerunlösliche Verbindung
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
ES2257795T3 (es) 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
US6348777B1 (en) 2000-02-29 2002-02-19 Alaris Medical Systems, Inc. Power management system
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
NZ537995A (en) 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
KR20060115350A (ko) 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
KR20060113737A (ko) * 2003-12-22 2006-11-02 쉐링 코포레이션 약제학적 조성물
DE102005041860A1 (de) 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
KR20080080087A (ko) 2005-09-30 2008-09-02 티티아이 엘뷰 가부시키가이샤 신규 약학 담체를 이용한 경피 약물 전달시스템, 장치 및방법
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
CA2698038A1 (en) 2007-07-26 2009-01-29 Entra Pharmaceuticals Inc. Systems and methods for delivering drugs
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
JP5785175B2 (ja) 2009-10-26 2015-09-24 石葯集団中奇制葯技▲術▼（石家庄）有限公司 スルホブチルエーテルシクロデキストリン塩を含有する内水相を有するリポソーム
US20120295893A1 (en) 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
ITRM20100630A1 (it) 2010-12-03 2012-06-04 Dyepower Procedimento di sintesi di complessi precursori e sensibilizzatori del biossido di titanio basati su complessi polipiridinici di rutenio.
EP2653479B1 (en) 2010-12-16 2015-12-02 Sumitomo Seika Chemicals Co. Ltd. Method for producing pseudopolyrotaxane aqueous dispersion
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US20130296437A1 (en) 2012-05-04 2013-11-07 E-Therapeutics Plc Treatment of Depression
CN104520326A (zh) 2012-06-21 2015-04-15 Ucb医药有限公司 药物制剂
US10124940B2 (en) 2012-09-11 2018-11-13 Zolo Solutions, Inc. Systems, methods, and devices for dispensing one or more substances
WO2014121235A2 (en) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
US9446186B2 (en) 2013-03-01 2016-09-20 Bigfoot Biomedical, Inc. Operating an infusion pump system
CN105437676B (zh) 2014-08-14 2020-03-24 上海利统生化制品有限公司 用于阻碍植物乙烯反应的层合物及其制备方法
FR3032353B1 (fr) 2015-02-06 2017-03-10 Jacques Seguin Composition pharmaceutique et dispositif pour le traitement de la douleur
CN108601891B (zh) 2016-01-12 2022-05-13 输液创新有限公司 输注设备
WO2017218918A1 (en) 2016-06-17 2017-12-21 Ys Pharmtech Stabilization of epinephrine formulations
DE102016014603A1 (de) 2016-06-30 2018-01-04 Thomas Herkenroth Synthetisches Ayahuasca
SG11201901147TA (en) 2016-08-25 2019-03-28 Validose Inc System and method for controlled medical therapy
BR102017016440A2 (pt) 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
US20200384188A1 (en) 2017-11-14 2020-12-10 Bexson Biomedical, Inc. Systems, devices, formulations and methods for controlled drug delivery
CN111330019B (zh) 2018-12-18 2022-03-15 中国人民解放军第二军医大学 氟马西尼包合物及其制备方法和应用
EP3968979B1 (en) * 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
US12576026B2 (en) 2020-07-08 2026-03-17 Extrovis Ag Formulations of nebivolol
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
EP4247386A4 (en) 2020-11-18 2024-12-18 Bexson Biomedical, Inc. FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS
EP4525916A4 (en) 2022-05-18 2026-05-20 Bexson Biomedical Inc LOW STOICHIOMETRIC RATIO SALT FORMULATIONS FOR COMPLEXING AGENTS OF PHARMACEUTICAL COMPOUNDS
WO2025111482A1 (en) 2023-11-22 2025-05-30 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072671A (ja) * 1993-03-05 1995-01-06 Univ Virginia Commonwealth 鎮痛剤
JPH11511466A (ja) * 1995-08-30 1999-10-05 スチュアート エル ウェグ 苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与
JP2002510653A (ja) * 1998-04-03 2002-04-09 カイロン コーポレイション 緩衝剤としてコハク酸を含有する注射可能なｉｇｆ処方物
JP2010525081A (ja) * 2007-04-26 2010-07-22 オースペックス・ファーマシューティカルズ・インコーポレイテッド 重水素標識ケタミン
JP2015501302A (ja) * 2011-10-14 2015-01-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2017180589A1 (en) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANADIAN JOURNAL OF ANAESTHESIA, vol. 37, no. 3, JPN6024015996, 1990, pages 385 - 386, ISSN: 0005314021 *
JOURNAL OF CLINICAL PSYCHIATRY, vol. 78, no. 7, JPN6024015999, 2017, pages 852 - 857, ISSN: 0005314023 *
PERITONEAL DIALYSIS INTERNATIONAL, vol. 31, JPN6024015997, 2011, pages 308 - 314, ISSN: 0005314022 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025114555A (ja) * 2019-05-15 2025-08-05 ベクソン バイオメディカル，インク． 皮下注射のためのケタミン製剤

Also Published As

Publication number Publication date
EP3968979C0 (en) 2026-07-01
US10973780B2 (en) 2021-04-13
EP3968979A4 (en) 2023-03-01
EP4792835A2 (en) 2026-08-19
US20200360308A1 (en) 2020-11-19
WO2020232274A1 (en) 2020-11-19
ES3075367T3 (en) 2026-08-04
US12636265B2 (en) 2026-05-26
CN121489917A (zh) 2026-02-10
CA3140046A1 (en) 2020-11-19
EP3968979A1 (en) 2022-03-23
JP2025114555A (ja) 2025-08-05
EP3968979B1 (en) 2026-07-01
US20210186896A1 (en) 2021-06-24
CN114126596A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
JP2025114555A (ja) 皮下注射のためのケタミン製剤
US12472201B2 (en) Complexing agent salt formulations of pharmaceutical compounds
EP2574168B9 (en) Topical formulation for a jak inhibitor
CN102781447B (zh) 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液
US20230405018A1 (en) Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators
JP7249670B2 (ja) アセトアミノフェン－プレガバリン組み合わせ及び疼痛を処置する方法
JP4959335B2 (ja) メチルフェニデート溶液および関連する投与および製造方法
US20240130994A1 (en) Ionic liquid formulations for treating diabetes
US20250345458A1 (en) Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios
EP3593819A1 (en) Compositions for therapeutic uses containing 5-htp and carbidopa
RU2716164C2 (ru) Стабильные композиции нейроактивных пептидов
US20260014191A1 (en) Complexing agent salt formulations of pharmaceutical compounds
US20240245617A1 (en) Lipid-based topical injection formulations
KR20190078455A (ko) 플루르비프로펜 함유 스프레이 조성물 및 그 제조방법
CN121537303A (zh) 非甾体抗炎药胆碱盐及其制备方法和应用
JP2024523932A (ja) ケトロラック液体組成物、その製造方法及び応用
HK1236852B (en) Aqueous solution comprising 3-quinuclidinone derivative for the treatment of hyperproliferative diseases, autoimmune diseases and heart diseases
HK1236852A1 (en) Aqueous solution comprising 3-quinuclidinone derivative for the treatment of hyperproliferative diseases, autoimmune diseases and heart diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241204